These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22058102)

  • 41. Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration.
    Trissel LA; Gilbert DL; Wolkin AC
    Int J Pharm Compd; 1999; 3(3):241-4. PubMed ID: 23985624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Compatibility of aztreonam with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1995 May; 52(10):1086-90. PubMed ID: 7656099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration.
    Woloschuk DM; Wermeling JR; Pruemer JM
    Am J Hosp Pharm; 1991 Oct; 48(10):2158-60. PubMed ID: 1781472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
    Kupie TC; Trusley C; Ben M; Trissel LA
    Am J Health Syst Pharm; 2008 Sep; 65(18):1735-59. PubMed ID: 18769000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drug additives.
    Kirschenbaum HL; Aronoff W; Perentesis GP; Plitz GW; Cutie AJ
    Am J Hosp Pharm; 1982 Jun; 39(6):1013-5. PubMed ID: 7102682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
    Kumar A; Mann HJ
    Am J Health Syst Pharm; 2010 Oct; 67(19):1640-4. PubMed ID: 20852166
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
    Trissel LA; Bready BB
    Am J Hosp Pharm; 1992 Jul; 49(7):1716-9. PubMed ID: 1352424
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF; Gilbert DL
    Am J Health Syst Pharm; 1997 Aug; 54(15):1735-41. PubMed ID: 9262747
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF; Baker MB; Walter WV; Mirtallo JM
    Am J Health Syst Pharm; 1997 Jun; 54(11):1295-300. PubMed ID: 9179351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam.
    Wade J; Cooper M; Ragan R
    Hosp Pharm; 2015 May; 50(5):376-9. PubMed ID: 26405323
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
    Rank DR; Friedland HD; Laudano JB
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects.
    Riccobene TA; Su SF; Rank D
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1496-504. PubMed ID: 23295928
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration.
    Ben M; Kupiec TC; Trusley C; Trissel LA
    Int J Pharm Compd; 2008; 12(5):460-2. PubMed ID: 23969872
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravenous Compatibility of Ceftazidime-Avibactam and Aztreonam Using Simulated and Actual Y-site Administration.
    O'Donnell JN; Xu A; Lodise TP
    Clin Ther; 2020 Aug; 42(8):1580-1586.e2. PubMed ID: 32684326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Compatibility and stability of diazepam injection following dilution with intravenous fluids.
    Morris ME
    Am J Hosp Pharm; 1978 Jun; 35(6):669-72. PubMed ID: 665679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF; Gilbert DL
    J Am Pharm Assoc (Wash); 1999; 39(4):514-8. PubMed ID: 10467816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection.
    Hanifah S; Nugroho B; Chabib L
    Anaesthesiol Intensive Ther; 2020; 52(1):23-27. PubMed ID: 32024349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions.
    Martinez JF; Trissel LA; Gilbert DL
    Int J Pharm Compd; 1997; 1(5):356-8. PubMed ID: 23989380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration.
    Mann HJ; Demmon SL; Boelk DA; Payne CA; Effron MB; Rajagopalan N; Williams MD; Beck GM; Gopalrathnam G
    Am J Health Syst Pharm; 2004 Dec; 61(24):2664-71. PubMed ID: 15646701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1993 Nov; 50(11):2359-63. PubMed ID: 8266963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.